Skip to content

Thailand HIV and Stigma Reduction Study

Optimizing Mobile Interventions to Overcome Stigma and Promote HIV Prevention

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06576648
Enrollment
154
Registered
2024-08-29
Start date
2025-02-20
Completion date
2027-08-14
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Exposure Prophylaxis

Keywords

Pre-Exposure Prophylaxis, HIV Prevention, mHealth, Stigma

Brief summary

This project will develop a multi-component, technology-delivered intervention designed to reduce HIV and intersectional stigma and improve the use of HIV pre-exposure prophylaxis (PrEP) among HIV-negative Thai vulnerable emerging adults (18-29 years).

Interventions

mHC is a four-session, 20-minute, motivational interviewing-based intervention, which will be delivered on the CIAS platform. It will be tailored to participants' responses given during the interaction in the intervention. In the first two sessions, the (virtual) counselor will motivate participants to overcome stigma and utilize HIV prevention services by using tailored motivational interviewing strategies, develop an individualized change goal based on their readiness, and provide cognitive behavioral strategies. In the last two sessions, the counselor will review the change plan, monitor progress, and provide support for sustained behavioral change. The sessions will occur within three months after baseline.

FRESH content includes six 10-15 minute sessions with interactive, culturally sensitive multimedia modules, which will be delivered on the CIAS platform. The content will aim to improve self-efficacy, reduce intersectional stigmas and promote HIV preventative behaviors. The sessions will occur within three months after baseline.

All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.

Sponsors

University of Massachusetts, Worcester
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Institute of HIV Research and Innovation Foundation, Thailand
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 29 Years
Healthy volunteers
Yes

Inclusion criteria

Aim 1 (Formative Research and Beta-Testing) Transgender women Inclusion Criteria: * Ages between 18 and 29 years * Male sex at birth * Self-identifies as women, transgender women or culturally identifies with the female spectrum * Laboratory-confirmed HIV-negative status * Self-reported recent history of condomless sex * Able to understand, read and speak Thai * Either not started PrEP or currently on PrEP but not adherent (taking ≤3 pills/week) in the past month.

Exclusion criteria

* Have a serious cognitive or psychiatric problem compromising ability to provide informed consent * Have active suicidal ideation or major mental illness at the time of interview (these patients will be referred for treatment) * Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance) * Currently enrolled in another HIV intervention study. Healthcare providers Inclusion criteria * Age 18 or above * Has provided HIV prevention or treatment services for TGW for at least one year

Design outcomes

Primary

MeasureTime frameDescription
PrEP stigmaBaseline, Month 3, and Month 6PrEP stigma will be evaluated with a 10-item, 5-point Likert scale. Higher scores indicate a higher level of perceived stigma surrounding PrEP.
Intervention Acceptability: System Usability Score (SUS)Month 3, Month 6The SUS is a 10-item, 5-point Likert scale for evaluating subjective usability. Each item is scored from 1 to 5, with the calculation involving either subtracting 1 from the user response or the user response from 5 depending on the item. The scores are then summed and multiplied by 2.5 to obtain a total score ranging from 0 to 100. A score above 80 indicates that the intervention is acceptable.
Intervention Acceptability: Exit InterviewMonth 3Participants will be asked about their experiences using mHC and FRESH content and potential improvements.
Intervention Feasibility: Participant retentionBaseline through Month 6Participant retention rate of over 85% at 6-month follow-up will be the minimum criterion for feasibility.
Intervention Feasibility: Number of FRESH sessions viewedBaseline through Month 6Intervention feasibility will be evaluated by the total number of FRESH sessions viewed.
Intervention Feasibility: Number of mHC sessions completedBaseline through Month 6Intervention feasibility will be evaluated by the number of completed intervention sessions.
PrEP Uptake: Self-reportMonth 3, Month 6PrEP uptake will be assessed using a self-report measure and confirmed via chart review and pharmacy records.
PrEP Adherence: Visual analog scaleBaseline, Month 3, and Month 6PrEP adherence will be assessed through the Young Adult Adherence Interview, which contains a visual analog scale (VAS) ranging from 0 to 100. Higher percentages on the VAS indicate greater adherence to ART.
PrEP Adherence: Self-Reported AdherenceBaseline, Month 3, and Month 6PrEP adherence will be evaluated through self-reported adherence over the past four weeks. Participants will rate their adherence on a scale ranging from 0 to 100%, with higher percentages indicating better adherence to PrEP. The result will be triangulated with DBS reports.
PrEP Adherence: DBS testingBaseline, Month 3, and Month 6PrEP adherence will be evaluated by tenofovir concentrations in dried blood spots (DBS). The result will be triangulated with self-reports.
HIV testing uptake: Self-reportBaseline, Month 3, and Month 6HIV testing uptake will be assessed via self-report and confirmed through chart review.
Intersectional stigmaBaseline, Month 3, and Month 6Intersectional stigma will be assessed using the Intersectional Discrimination Index, which includes three subsets: anticipated, day-to-day, and major discrimination. The anticipated and day-to-day discrimination measures each consist of 9 items, while the major discrimination measure includes 13 items. The anticipated discrimination score is calculated as a mean ranging from 0 to 4. The day-to-day discrimination score is based on frequency and can range from 0-9 (lifetime) or 0-18 (past-year). The major discrimination score is based on frequency and can range from 0-26 (lifetime) or 0-13 (past-year). For all three measures, higher scores indicate a greater level of anticipated discrimination or experienced discrimination.
Internalized stigmaBaseline, Month 3, and Month 6Internalized stigma will be evaluated using the Internalized AIDS-related Stigma Scale, a 6-item scale. Scores range from 0 to 6, with higher scores indicating greater internalized stigma.
Perceived stigmaBaseline, Month 3, and Month 6Perceived stigma will be evaluated using a 13-item, 4-point Likert scale, with a maximum score of 52. Higher scores indicate a higher level of perceived stigma.
Anticipated stigmaBaseline, Month 3, and Month 6Anticipated stigma will be evaluated from three different sources (friends and family, neighbors, and others in the community, and healthcare workers) using a 9-item, 5-Likert scale. Scores can reach up to 45, with higher scores indicating a greater expectation of experiencing stigma in the future.
Enacted stigmaBaseline, Month 3, and Month 6Enacted stigma will be evaluated with an 8-item, 4-point Likert scale enacted stigma scale. The total score can reach up to 32, with higher scores indicating having more stigma experiences.

Secondary

MeasureTime frameDescription
Social supportBaseline, Month 3, and Month 6Social support will be assessed using the Social Provision Scale (13-item, 5-point Likert scale). The survey assesses the availability of five forms of social supportsd: attachment, guidance, social integration, reliable alliance, and reassurance of worth. Scores range from 13 to 65, with higher scores indicating receiving a higher level of social support.
EmpowermentBaseline, Month 3, and Month 6Empowerment will be assessed using the Healthcare Empowerment Inventory. It's an 8-item, 5-point Likert scale, with total scores ranging from 8 to 40. Higher scores indicate a greater sense of empowerment in her health care.
Information: HIV KnowledgeBaseline, Month 3, and Month 6HIV transmission risk awareness will be assessed through an 18-item HIV Knowledge Questionnaire. The total scores can range from 0 to 18, with higher scores indicating a higher level of HIV knowledge.
Information: PrEP KnowledgeBaseline, Month 3, and Month 6PrEP knowledge will be assessed through a 13-item PrEP Knowledge Scale. The total score can range from 0 to 13, with higher scores indicating a higher level of PrEP knowledge.
Motivation: Rollnick's Readiness RulerBaseline, Month 3, and Month 6Motivation will be evaluated using the 5-item Rollnick's Readiness Ruler. Each item ranges from 0 to 10, with higher scores indicating a greater readiness for change in HIV prevention and risk behaviors.
Behavioral SkillsBaseline, Month 3, and Month 6Behavioral skills will be assessed using an adapted version of the Self-Efficacy for Health Promotion and Risk Reduction Questionnaire. This 8-item, 5-point Likert scale measures confidence levels in HIV prevention behaviors, including condom use and adherence to the PrEP schedule. Higher scores indicate a greater confidence in health promotion and HIV prevention.
HIVBaseline, Month 3, and Month 6Fourth-generation HIV-1/2 antigen/antibody combi testing will be used to detect HIV infection.
STIBaseline and Month 6Treponemal test with rapid plasma reagin (RPR) will be used for syphilis, while urine, oropharyngeal, and rectal swabs will be used for gonorrhea and chlamydia.
Sexual RiskBaseline, Month 3, and Month 6Sexual risk will be assessed using a Timeline Followback interview via CASI for any risky sexual behavior over the past 30 days.
Adaptive copingBaseline, Month 3, and Month 6Adaptive coping will be assessed by the Brief Resilient Coping Scale, a four-item, 5-point Likert scale questionnaire. Higher scores indicate greater resilient coping.
ResilienceBaseline, Month 3, and Month 6Resilience will be assessed by the Connor-Davidson Resilience Scale. It is a 10-item, 5-point Likert scale questionnaire, with scores ranging from 0 to 40. Higher scores indicate a greater ability to cope with challenges.
Substance use: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)Baseline, Month 3, and Month 6Substance use will be assessed with ASSIST, an 8-item questionnaire that measures the use of ten substances, including alcohol, smoking, cannabis, and other drugs. Each item is scored from 0 to 12, resulting in a risk score for each ranging from 0 to 31 for tobacco and 0 to 39 for alcohol and other drugs. Higher scores indicate a higher risk of substance use disorder.
Substance use: Alcohol Use Disorder Identification Text (AUDIT-C)Baseline, Month 3, and Month 6Substance use, specifically alcohol use disorder, will be assessed by using AUDIT-C. Each item is scored from 0 to 4, with 0 indicating no alcohol consumption and 4 indicating more hazardous drinking habits. The total score can range up to 12, with higher scores suggesting greater risks of hazardous alcohol consumption.
Mental healthBaseline, Month 3, and Month 6Mental health will be evaluated using the Thai General Health Questionnaire. The questionnaire has 12 4-point Likert scale items that assess psychological distress, including depression and anxiety. Scores range up to 48, with higher scores indicating a higher level of psychological distress.
Perceived HIV riskBaseline, Month 3, and Month 6Perceived HIV risk will be assessed using the Perceived Risk of HIV Scale (8 item, 4-point Likert scale). The score ranges up to 40-, with higher scores indicating a high level of perception in HIV risk.
Motivation: Decisional Balance for Problem BehaviorBaseline, Month 3, and Month 6Motivation will be assessed using the Decisional Balance for Problem Behavior scale. This 36-item, 5-point Likert scale evaluates the perceived pros and cons of using PrEP.

Countries

Thailand

Contacts

CONTACTDeogwoon Kim, PhD
Deogwoon.Kim13@umassmed.edu586-703-4899
PRINCIPAL_INVESTIGATORBo Wang, PhD

University of Massachusetts, Worcester

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026